The #Beneluxa Initiative welcomes two new #JCA reports prepared by #NCPE, together with #IQWiG on tarlatamab (IMDYLLTRA) and #HAS on onasemnogene abeparvovec (ITVISMA). đź“š We invite respective companies to submit for national #HTA, as the reports will contribute to evidence-based decision-making.
@beneluxainitiative.bsky.social